COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

MAP to Provide Access to Crizanlizumab, for Sickle Cell Disease Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03720626
Expanded Access Status : Available
First Posted : October 25, 2018
Last Update Posted : March 10, 2020
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Tracking Information
First Submitted Date October 24, 2018
First Posted Date October 25, 2018
Last Update Posted Date March 10, 2020
Descriptive Information
Brief Title MAP to Provide Access to Crizanlizumab, for Sickle Cell Disease Patients
Brief Summary The purpose of this Cohort Treatment Plan is to allow access to crizanlizumab (SEG101) for eligible patients diagnosed with sickle cell disease (SCD) to prevent or reduce the frequency of vaso-occlusive crises (VOC). The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.
Detailed Description Not Provided
Study Type Expanded Access
Expanded Access Type Treatment IND/Protocol
Intervention Drug: crizanlizumab
IV formulation with 30 min infusion, 5mg/kg dosage
Other Name: SEG101
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Expanded Access Status Available
Contact: Novartis Pharmaceuticals +41613241111
Contact: Novartis Pharmaceuticals
Listed Location Countries Not Provided
Removed Location Countries  
Administrative Information
NCT Number NCT03720626
Responsible Party Novartis ( Novartis Pharmaceuticals )
Study Sponsor Novartis Pharmaceuticals
Collaborators Not Provided
Investigators Not Provided
PRS Account Novartis
Verification Date March 2020